Granted Patent
B2
US 12,357,693 · App. 17/752,676 · Granted Jul 15, 2025
Method for inducing tumor regression
Assignee:
VeroScience LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.
Claims (23)
1. A method of treating a malignant brain tumor in a subject comprising:
1) administering at least one of glucose, glucagon, corticosteroids, growth hormones, thyroid hormones and insulin, to the subject until the plasma glucose level of the subject is above the basal plasma glucose of the subject;
2) administering at least one EtNBS compound to the subject; and thereafter
3) exposing the subject to actinic light.
2. The method of claim 1 wherein the malignant tumor is a glioma.
3. The method of claim 2 wherein the glioma is a glioblastoma.
4. The method of claim 1 , comprising administering glucose to the subject.
5. The method of claim 1 , comprising administering one or more hormones to the subject.
6. The method of claim 1 , comprising waiting at least 30 minutes between administration of the EtNBS compound to the subject and exposing the subject to actinic light.
7. The method of claim 1 comprising increasing the plasma glucose level of the subject by at least 10,15, 20, 25, 30, 35, 40, 45 or 50% above the basal plasma glucose level of the subject.
8. The method of claim 1 wherein the actinic light comprises light in the range of wavelength 600-700 nm.
9. The method of claim 1 which comprises administering to the subject between about 0.01 to 15 mg/kg of body weight of at least one EtNBS compound.
10. The method of claim 6 wherein the actinic light comprises laser light.
11. The method of claim 1 wherein the actinic light delivers total light energy of between about 50 and about 500 Joules (J)/cm2.
12. The method of claim 1 wherein the power density of the light is between about 50 and 500 mW/cm.
13. The method of claim 1 wherein the time period after glucose administration and exposure to actinic light is about 30 to 60 minutes.
14. The method of claim 1 comprising administering glucagon to the subject.
15. The method of claim 1 comprising administering corticosteroids to the subject.
16. The method of claim 1 comprising administering growth hormones to the subject.
17. The method of claim 1 , comprising administering thyroid hormones to the subject.
18. The method of claim 1 , comprising administering insulin to the subject.
19. The method of claim 1 , comprising administering glucose and insulin to the subject.
20. The method of claim 1 wherein the EtNBS compound is 2-iodo-5-ethylamino-9-diethylamino-benzo [a]phenothiazinium chloride.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 27, 2022
From: CINCOTTA, ANTHONY H.
To: VEROSCIENCE LLC
Reel/Frame 060037/0946 →
Continuity (3)
Provisional Application
62904430
· Sep 23, 2019
References Cited (257)
US 941005A
· Brandt
· 1909
[cited by applicant]
US 3752814A
· Fluckiger
· 1973
[cited by applicant]
US 4654345A
· Cavanak
· 1987
[cited by applicant]
US 4659715A
· Meier et al.
· 1987
[cited by applicant]
US 4749709A
· Meier et al.
· 1988
[cited by applicant]
US 4783469A
· Meier et al.
· 1988
[cited by applicant]
US 4962197A
· Foley et al.
· 1990
[cited by applicant]
US 5006526A
· Meier et al.
· 1991
[cited by applicant]
US 5066495A
· Moro et al.
· 1991
[cited by applicant]
US 5186420A
· Beauchamp et al.
· 1993
[cited by applicant]
US 5344832A
· Cincotta et al.
· 1994
[cited by applicant]
US 5468755A
· Cincotta et al.
· 1995
[cited by applicant]
US 5496803A
· Meier et al.
· 1996
[cited by applicant]
US 5523082A
· Corbiere
· 1996
[cited by applicant]
US 5554623A
· Cincotta et al.
· 1996
[cited by applicant]
US 5565454A
· Cincotta
· 1996
[cited by applicant]
US 5585347A
· Meier et al.
· 1996
[cited by applicant]
US 5626860A
· Cincotta et al.
· 1997
[cited by applicant]
US 5635512A
· Cincotta et al.
· 1997
[cited by applicant]
US 5654313A
· Cincotta et al.
· 1997
[cited by applicant]
US 5668155A
· Cincotta et al.
· 1997
[cited by applicant]
US 5679685A
· Cincotta et al.
· 1997
[cited by applicant]
US 5688794A
· Meier et al.
· 1997
[cited by applicant]
US 5696128A
· Meier et al.
· 1997
[cited by applicant]
US 5700795A
· Meier et al.
· 1997
[cited by applicant]
US 5700800A
· Cincotta et al.
· 1997
[cited by applicant]
US 5712265A
· Meier et al.
· 1998
[cited by applicant]
US 5714519A
· Cincotta et al.
· 1998
[cited by applicant]
US 5716932A
· Meier et al.
· 1998
[cited by applicant]
US 5716933A
· Meier et al.
· 1998
[cited by applicant]
US 5716957A
· Cincotta et al.
· 1998
[cited by applicant]
US 5716962A
· Cincotta et al.
· 1998
[cited by applicant]
US 5719160A
· Cincotta et al.
· 1998
[cited by applicant]
US 5731287A
· Meier et al.
· 1998
[cited by applicant]
US 5731312A
· Cincotta et al.
· 1998
[cited by applicant]
US 5741503A
· Cincotta et al.
· 1998
[cited by applicant]
US 5744477A
· Meier et al.
· 1998
[cited by applicant]
US 5750519A
· Cincotta et al.
· 1998
[cited by applicant]
US 5756513A
· Meier et al.
· 1998
[cited by applicant]
US 5760047A
· Meier et al.
· 1998
[cited by applicant]
US 5792748A
· Meier et al.
· 1998
[cited by applicant]
US 5814638A
· Lee et al.
· 1998
[cited by applicant]
US 5830895A
· Cincotta et al.
· 1998
[cited by applicant]
US 5854255A
· Cincotta et al.
· 1998
[cited by applicant]
US 5866584A
· Cincotta et al.
· 1999
[cited by applicant]
US 5872127A
· Meier et al.
· 1999
[cited by applicant]
US 5872133A
· Meier et al.
· 1999
[cited by applicant]
US 5877183A
· Cincotta
· 1999
[cited by applicant]
US 5902811A
· Cincotta
· 1999
[cited by applicant]
US 5905083A
· Meier et al.
· 1999
[cited by applicant]
US 5952329A
· Cincotta et al.
· 1999
[cited by applicant]
US 6004972A
· Meier et al.
· 1999
[cited by applicant]
US 6071914A
· Meier et al.
· 2000
[cited by applicant]
US 6075020A
· Meier et al.
· 2000
[cited by applicant]
US 6855707B2
· Cincotta
· 2005
[cited by applicant]
US 7888310B2
· Cincotta
· 2011
[cited by applicant]
US 8021681B2
· Cincotta
· 2011
[cited by applicant]
US 8137992B2
· Cincotta
· 2012
[cited by applicant]
US 8137993B2
· Cincotta
· 2012
[cited by applicant]
US 8137994B2
· Cincotta
· 2012
[cited by applicant]
US 8431155B1
· Cincotta et al.
· 2013
[cited by applicant]
US 8613947B2
· Cincotta et al.
· 2013
[cited by applicant]
US 8741918B2
· Cincotta
· 2014
[cited by applicant]
US 8821915B2
· Cincotta
· 2014
[cited by applicant]
US 8877708B2
· Cincotta
· 2014
[cited by applicant]
US 9192576B2
· Cincotta et al.
· 2015
[cited by applicant]
US 9205084B2
· Cincotta
· 2015
[cited by applicant]
US 9352025B2
· Cincotta
· 2016
[cited by applicant]
US 9364515B2
· Cincotta
· 2016
[cited by applicant]
US 9415005B2
· Cincotta
· 2016
[cited by applicant]
US 9522117B2
· Cincotta et al.
· 2016
[cited by applicant]
US 9655865B2
· Cincotta
· 2017
[cited by applicant]
US 9700555B2
· Cincotta et al.
· 2017
[cited by applicant]
US 9895422B2
· Cincotta
· 2018
[cited by applicant]
US 9925186B2
· Cincotta
· 2018
[cited by applicant]
US 9993474B2
· Cincotta et al.
· 2018
[cited by applicant]
US 9999653B2
· Cincotta
· 2018
[cited by applicant]
US 20010016582A1
· Cincotta
· 2001
[cited by applicant]
US 20010049350A1
· Cincotta et al.
· 2001
[cited by applicant]
US 20020146400A1
· Cincotta
· 2002
[cited by applicant]
US 20040028613A1
· Quay
· 2004
[cited by applicant]
US 20040077679A1
· Cincotta
· 2004
[cited by applicant]
US 20040081678A1
· Cincotta
· 2004
[cited by applicant]
US 20040102383A1
· Cincotta et al.
· 2004
[cited by applicant]
US 20040220190A1
· Cincotta
· 2004
[cited by applicant]
US 20050054652A1
· Cincotta
· 2005
[cited by applicant]
US 20050054734A1
· Cincotta
· 2005
[cited by applicant]
US 20050215558A1
· Cincotta
· 2005
[cited by applicant]
US 20060258589A1
· McTavish
· 2006
[cited by applicant]
US 20080200453A1
· Cincotta
· 2008
[cited by applicant]
US 20090110674A1
· Loizou
· 2009
[cited by applicant]
US 20090137598A1
· Cincotta
· 2009
[cited by applicant]
US 20100035886A1
· Nivorozhkin et al.
· 2010
[cited by applicant]
US 20130274246A1
· Cincotta
· 2013
[cited by applicant]
US 20140051685A1
· Cincotta
· 2014
[cited by applicant]
US 20140275235A1
· Deleyrolle et al.
· 2014
[cited by applicant]
US 20150011554A1
· Cincotta et al.
· 2015
[cited by applicant]
US 20170209539A1
· Cincotta
· 2017
[cited by applicant]
US 20170305898A1
· Cincotta
· 2017
[cited by applicant]
US 20170340271A1
· Cincotta
· 2017
[cited by applicant]
US 20180177874A1
· Cincotta
· 2018
[cited by applicant]
US 20190160059A1
· Cincotta et al.
· 2019
[cited by applicant]
US 20210401824A1
· Cincotta
· 2021
[cited by applicant]
US 20220125379A1
· Cincotta
· 2022
[cited by applicant]
US 20220142960A1
· Cincotta et al.
· 2022
[cited by applicant]
CA 2166204
· 2009
[cited by applicant]
CN 102283844
· 2014
[cited by applicant]
CN 102727894
· 2015
[cited by applicant]
GB 2192541
· 1988
[cited by applicant]
JP H02121919
· 1990
[cited by applicant]
JP 2021500357
· 2021
[cited by applicant]
WO WO2002083141
· 2002
[cited by applicant]
WO WO2009091576
· 2009
[cited by applicant]
WO WO2013165902
· 2013
[cited by applicant]
WO WO2017184875
· 2017
[cited by applicant]
WO WO2020011854A1
· 2020
[cited by applicant]
WO WO2021019231A1
· 2021
[cited by applicant]
Hendrzak-Henion et al (Year: 1999).
[cited by examiner]
Fan et al (Year: 1995).
[cited by examiner]
Alkarakooly et al., “Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells,” PLOS One, Oct. 23, 2018, 13(10):e0206182.
[cited by applicant]
Liu et al., “EtNBSe-PDT inhibited proliferation and induced autophagy of HNE-1 cells via downregulating the Wnt/beta-catenin signaling pathway,” Photodiagnosis and Photodynamic Therapy, Mar. 1, 2019, 26:65-72.
[cited by applicant]
[No Author Listed], “Dissolution,” General Chapter 711, U.S. Pharmacopoeia (USP), 34th ed., Dec. 1, 2011, 8 pages.
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 1977, 66(1):1-19.
[cited by applicant]
Dietrich et al., “Non-alcoholic fatty liver disease, obesity and the metabolic syndrome,” Best Practice & Research Clinical Gastroenterology, 2014, 28:637-653.
[cited by applicant]
EP Extended European Search Report in European Appln No. 18868516.8, dated Jun. 29, 2021, 8 pages.
[cited by applicant]
Gould, “Salt selection for basic drugs,” International Journal of Pharmaceutics, 1986, 33:201-217.
[cited by applicant]
Pan, “Industrial Pharmaceutics,” China Medical Science and Technology Press, the first printing of the 3rd edition, Aug. 2015, p. 47 (Partial English Translation only).
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln PCT/US2018/056554, dated Apr. 21, 2020, 15 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in Application No. PCT/US2017/028656, mailed on Jul. 7, 2017, 13 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appl. PCT/US2018/056554, dated, Jan. 3, 2019, 17 pages.
[cited by applicant]
Pukngam et al., “Development and Validation of a Stability-Indicating HPLC Method for Determination of Bromocriptine Mesylate in Bulk Drug and Tablets,” Current Pharmaceutical Analysis, 2013, 9:92-101.
[cited by applicant]
Rathbone et al., academia.edu [Online], “Modified-Release Drug Delivery Technology,” Marcel Dekker, Inc., 2003, [Retrieved on Nov. 23, 2018], retrieved from: URL<https:www.academia.edu/28583222/Modified-Release Drug Del…
[cited by applicant]
Rowe et al., “Mannitol,” Handbook of Pharmaceutical Excipients, 7th ed., 2012, 479-482.
[cited by applicant]
Rowe et al., “Stearic Acid,” Handbook of Pharmaceutical Excipients, 6th ed, 2009, 697-699.
[cited by applicant]
Singh et al., “Dosage Forms: Non-Parenteral,” Encyclopedia of Pharmaceutical Technology, 2008, 749-761.
[cited by applicant]
Stahl et al., “Pharmaceutical Salts: Properties, Selection, and Use,” Wiley-VCH, IUPAC, 2002, 329-345.
[cited by applicant]
Vicchi et al., “Dopaminergic drugs in type 2 diabetes and glucose homeostasis,” Pharmacological Research, 2016, 109:74-80.
[cited by applicant]
Granchi et al., “Anti-cancer agents counteracting tumor glycolysis,” ChemMedChem, Aug. 2012, 7(8):1318-1350.
[cited by applicant]
Sun et al., “Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors,” Photochem. Photobiol. Science, Jul. 16, 2002, 1:690-695.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2017/028656, mailed on Oct. 23, 2018, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/052278, dated Mar. 15, 2022, 7 pages.
[cited by applicant]
Office Action in Japanese Appln. No. 2023-018110, mailed on Apr. 2, 2024, 5 pages (with English translation).
[cited by applicant]
Ashton et al., “Oxidative Phosphorylation as an Emerging Target in Cancer Therapy,” Clinical Cancer Research, 2018, 24(11):2482-2490.
[cited by applicant]
Cincotta et al., “Novel benzophenothiazinium photosensitizers: preliminary in-vivo results,” Photodynamic Therapy: Mechanisms II, SPIE, 1990, 1203:202-210.
[cited by applicant]
Cincotta et al., “Novel Phenothiazinium Photosensitizers for Photodynamic Therapy,” SPIE Proceedings, Advances in Photochemotherapy, 1988, 997:145-153.
[cited by applicant]
Cincotta et al., “Novel Photodynamic Effects of a Benzophenothiazine on Two Different Murine Sarcomas,” Cancer Research, Mar. 1, 1994, 54:1249-1258.
[cited by applicant]
Cincotta et al., “Novel red absorbing benozo[a]phenoxazinium and benzo[a]phenothiazinium photosensitizers: in vitro evaluation,” PhotoChemistry and PhotoBiology, Nov. 1987, 46(5):751-758.
[cited by applicant]
Cincotta et al., “Phototoxicity, Redox Behavior, and Pharmacokinetics of Benzophenoxazine Analogues in EMT-6 Murine Sarcoma Cells,” Cancer Research, Jun. 1, 1993, 53:2571-2580.
[cited by applicant]
Deni et al., “Glucose-functionalized amino-OPEs as biocompatible photosensitizers in PDT,” European Journal of Medicinal Chemistry, Jan. 28, 2016, 11:58-71.
[cited by applicant]
Fadlan et al., “Synthesis, photophysical properties, and photodynamic activity of positional isomers of TFPP-glucose conjugates,” Bioorganic & Medicinal Chemistry, Feb. 19, 2018, 26(8):1848-1858.
[cited by applicant]
Fadok et al., “Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: roles of proteases,” Journal of Immunology, 2001, 166:6847-6854.
[cited by applicant]
Fan et al., “Hyperglycemia enhances the effectiveness of PDT,” Proceedings of SPIE, 1995, 2392:36-39.
[cited by applicant]
Feng et al., “Energy metabolism targeted drugs synergize with photodynamic therapy to potentiate breast cancer cell death,” Photochemical & Photobiological Science, Oct. 9, 2014, 13:1792-1803.
[cited by applicant]
Foley et al., “Structure and Properties of Novel Benzo[α]Phenoxazinium Photochemotherapeutic Agents,” SPIE Proceedings, New Directions in Photodynamic Therapy, 1987, 847:90-95.
[cited by applicant]
Foultier et al., “Photosensitization of L12 10 leukemic cells by argon laser irradiation after incubation with haematoporphyrin derivative and rhodamine 123,” J Photochem. Photobiol. B: Biol. 1991, 10:119-132.
[cited by applicant]
Granchi et al., “Anti-cancer agents counteracting tumor glycolsis,” ChemMedChem, Aug. 2012, 7(8):1318-1350.
[cited by applicant]
Hayashi et al., “A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages,” Molecular Cancer Therapeutics, 2015, 14(2):452-460.
[cited by applicant]
Hendrzak-Henion et al., “Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy,” Photochemistry and Photobiology, 1999, 69(5):575-581.
[cited by applicant]
Lin et al., “Lysosomal Localization and Mechanism of Uptake of Nile Blue Photosensitizers in Tumor Cells,” Cancer Research, 1991, 51:2710-2719.
[cited by applicant]
Lin et al., “Photosensitization, Uptake, and Retention of Phenoxazine Nile Blue Derivatives in Human Bladder Carcinoma Cells,” Cancer Research, 1991, 51:1109-1116.
[cited by applicant]
Martin et al., “A concomitant ATP-depleting strategy markedly enhances anticancer agent activity,” Apoptosis, 2001, 6(1/2):125-131.
[cited by applicant]
Nelson et al., “Glucose administration combined with photodynamic therapy of cancer improves therapeutic efficacy,” Lasers in Surgery and Medicine, 1992, 12:153-158.
[cited by applicant]
Nishie et al., “Excellent antitumor effects for gastrointestinal cancers using photodynamic therapy with a novel glucose conjugated chlorin e6,” Biochemical and Biophysical Research Communications, Jan. 2018, 496(4):120…
[cited by applicant]
Oberdanner et al., “Glucose is Required to Maintain High ATP-levels for the Energy-utilizing Steps During PDT-induced Apoptosis,” Photochemistry and Photobiology, 2002, 76(6):695-703.
[cited by applicant]
Osinsky et al., “Tumour pH under induced hyperglycemia and efficacy of chemotherapy,” Anticancer Research, 1987, 7(2):199-201.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/052278, dated Feb. 10, 2021, 9 pages.
[cited by applicant]
Pelicano et al., “Glycolysis inhibition for anticancer treatment,” Oncogene, 2006, 25:4633-4646.
[cited by applicant]
Ramu et al., “Glucose-appended platinum(II)-BODIPY conjugates for targeted photodynamic therapy in red light,” Inorganic Chemistry, Feb. 5, 2018, 57(4):1717-1726.
[cited by applicant]
Reiter et al., “Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities,” Journal of Immunology, 1999, 163:1730-1732.
[cited by applicant]
Sauter et al., “Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells,” Journal of Experimental Medici…
[cited by applicant]
Sun et al., “Neutrphils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors,” Photochem. Photobiol. Science, Jul. 16, 2002, 1:690-695.
[cited by applicant]
Uruma et al., “Synthesis and biological evaluation of glucose conjugated phthalocyanine as a second-generation photosensitizer,” Bioorganic & Medicinal Chemistry, Jun. 4, 2019, 27:3279-3284.
[cited by applicant]
Detty et al., “Current clinical and preclinical photosensitizers for use in photodynamic therapy,” Journal of Medicinal Chemistry, 2004, 47(16):3897-3915.
[cited by applicant]
Frimberger et al., “Photodynamic Therapy of Naturally Occurring Tumors in Animals Using a Novel Benzophenothiazine Photosensitizer,” Clinical Cancer Research, 1998, 4:2207-2218.
[cited by applicant]
Office Action in European Appln No. 21189773.1, mailed on Sep. 16, 2024, 5 pages.
[cited by applicant]
Dolmans et al., “Photodynamic therapy for cancer,” Nat Rev Cancer, May 2003, 3(5):380-387.
[cited by applicant]
Bergamaschi et al., “Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine,” Anal Bioanal Chem, May 2013, available online Mar. 15, 2013, 405(14):4679-4689 (Author Manuscript, 19 pages).
[cited by applicant]
fda.gov [online], “Data Standards Manual (monographs),” Feb. 27, 2018, retrieved on Jan. 15, 2025, retrieved from URL<https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/data-standards-manual-monograph…
[cited by applicant]
Giron-Forest et al., “Bromocriptine Methanesulphonate”, Analytical Profiles of Drug Substances, 1979, vol. 8, pp. 47-81 (Abstract Only).
[cited by applicant]
Hurd et al., “Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial,” Am J Psychiatry, Nov. 1, 2019, …
[cited by applicant]
Hurd et al., “Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage,” Neurotherapeutics, Oct. 2015, 12(4):807-815.
[cited by applicant]
Hurd, “Leading the Next CBD Wave-Safety and Efficacy,” JAMA Psychiatry, Apr. 1, 2020, 77(4):341-342.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2023/026236, mailed on Jan. 2, 2025, 11 pages.
[cited by applicant]
International Search Report in International Appln. No. PCT/US2023/026236, mailed on Jan. 10, 2024, 15 pages.
[cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee in International Appln. No. PCT/US2023/026236, mailed on Sep. 28, 2023, 2 pages.
[cited by applicant]
Manini et al., “Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans,” J Addict Med, May-Jun. 2015, 9(3):204-210 (Author Manuscript, 17 pages).
[cited by applicant]
Office Action (Notification of Reexamination) in Chinese Appln. No. 201780038243.6, mailed on Jan. 14, 2025, 22 pages (with English translation).
[cited by applicant]
Ren et al., “Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances,” J Neurosci, Nov. 25, 2009, 29(47): 14764-14769.
[cited by applicant]
Tavares et al., “Mucuna pruiens treatment shows anti-obesity and intestinal health effects in obese rats,” Food & Function, Feb. 25, 2021, 12(11): 6479-6489 (Accepted Manuscript, 13 pages).
[cited by applicant]
Tsai et al., “Bromocriptine (B) plus Curcumin (C) Synergize to Reduce Nonalcoholic Steatohepatitis (NASH) in Mice,” Diabetes, Jun. 1, 2019, 68(Supplement_1):1850-P.
[cited by applicant]
Tsai et al., “Bromocriptine (B) plus Curcumin(C) Interact to Reduce Advanced Fibrosis in a Mouse Methionine-Choline Deficient (MCD) Diet Model of Nonalcoholic Steatohepatitis (NASH),” Diabetes, Jun. 1, 2019, 68(Suppleme…
[cited by applicant]
Tsai et al., Bromocriptone (BC) Improves Hepatic Steatosis, Inflammation, and ER Stress in a Mouse Obesogenic Dietary Model of Nonalcoholic Steatohepatitis (NASH), Diabetes, Jun. 1, 2019, 68(Supplement_1):1868-P.
[cited by applicant]